Thursday, October 31, 2013

Drug Discovery@nature.com 31 October 2013

Drug Discovery

Advertisement
This Is Your Brain on Drugs
TABLE OF CONTENTS

31 October 2013

News
Analysis
Research Highlights
Research & Reviews
Careers

Nature Reviews Drug Discovery is on Twitter

Advertisement
Nature Collections
TCGA pan-cancer analysis


The Cancer Genome Atlas Pan-cancer initiative examines the similarities and differences among the genomic and cellular alterations found in the first dozen tumor types to be profiled by TCGA. This first look across cancer offers new tools in genomics and bioinformatics and the prospect of repurposing targeted therapies directed by the molecular pathology of the tumors in addition to their clinical classification.

View the Collection and accompanying Podcast, FREE at: 
www.nature.com/tcga


Produced with support from 
Illumina
 

News

Top

Rodent immune to scorpion venom
doi:10.1038/nature.2013.14014
Mechanism for pain resistance in grasshopper mice suggests potential drug target.
Full Text

China enters global vaccine marketplace
doi:10.1038/nature.2013.13975
First World Health Organization endorsement of a Chinese-made vaccine may offer cheap, high quality jabs for the developing world.
Full Text

Extra gene makes mice manic
doi:10.1038/nature.2013.14016
But common drug can be used to control symptoms.
Full Text

Cultured follicles offer hope for beating baldness
doi:10.1038/nature.2013.13983
Old cell-growth method moves hair restoration technique from mice to humans.
Full Text

Analysis

Top

A platform for RNA
doi:10.1038/scibx.2013.1151
An information explosion on the numbers and mechanisms of functional RNAs has spurred oligonucleotide-based therapeutic development. Pharmas and big biotechs are carving up the space via partnerships, adding multiple nucleic acid–based technologies to their drug discovery toolboxes.
Full Text

Pharmaceutical forecasting: throwing darts?
doi:10.1038/nrd4127
Forecasting of the future commercial value of drugs is a crucial activity that affects many decisions by pharmaceutical companies. However, this analysis indicates that many forecasts are wrong, often substantially.
Full Text

Research Highlights

Top

Anticancer drugs: Stapled peptide reactivates p53
doi:10.1038/nrd4133
The stapled α-helical peptide ATSP-7041 - which is a specific dual inhibitor of MDM2 and MDMX - effectively induces p53-dependent apoptosis and inhibits cell proliferation in mouse models of human tumours.
Full Text

Biotechnology: Rice-derived rotavirus antibody shows promise
doi:10.1038/nrd4131
Researchers have genetically engineered rice to produce high yields of a rotavirus-specific antibody fragment in the seeds. This antibody was effective in treating and preventing rotavirus-induced gastrointestinal symptoms in mice.
Full Text

Neurodegenerative diseases: New kinase targets for Alzheimer's disease
doi:10.1038/nrd4132
Two recent studies show that inhibiting kinases involved in the regulation of amyloid precursor protein processing or protein synthesis by eukaryotic translation initiation factor 2α attenuates disease progression in mice.
Full Text

Research & Reviews

Top

Considerations for the successful co-development of targeted cancer therapies and companion diagnostics
doi:10.1038/nrd4101
The authors discuss issues relating to the co-development of targeted cancer therapies and companion diagnostics that were not covered in depth in the draft guidance released by the US FDA in 2011. They also propose potential strategies that will be useful to mitigate challenges and to help guide the future co-development of drugs and diagnostics.
Full Text

Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology
doi:10.1038/nrc3580
Anaplastic lymphoma kinase (ALK) is commonly altered - through mutation, overexpression or translocation - in many types of cancer, but the role of ALK signalling in mammalian cells and tumours remains enigmatic. What can we learn from model systems? And what progress has been made in targeting this receptor tyrosine kinase?
Full Text

p11 and its role in depression and therapeutic responses to antidepressants
doi:10.1038/nrn3564
Recent studies have shown that the protein p11 (also known as S100A10) has an important role in depression-like behaviour and antidepressant actions. Greengard and colleagues discuss the molecular and cellular mechanisms that may underlie this role.
Full Text

Macrophages in atherosclerosis: a dynamic balance
doi:10.1038/nri3520
In this Review, the authors provide a comprehensive overview of the role of macrophage dynamics in determining the initiation, progression and regression of atherosclerotic inflammation. Understanding the factors that determine the inflammatory state of the plaque may help to identify potential therapeutic targets for plaque regression.
Full Text

Drug Discovery
JOBS of the week
PhD Project: Blood-brain Barrier Drug Targeting by Mass Spectrometry Imaging in Early ADME Profiling
Uppsala University
Key Postdoctoral Positions Available At Wits Advanced Drug Delivery Platform
University of the Witwatersrand, Johannesburg, South Africa
Postdoc Position � Cancer Drug Resistance
Brigham & Women's Hospital - Harvard Medical School
Senior Project Manager Drug Discovery and Development (m / f)
Akron Molecules GmbH
Medical Director, Global Drug Safety Product Leader (m / f)
Merck Group
More Science jobs from
Drug Discovery
EVENT
6th International Conference on Drug Discovery and Therapy
10.02.14
Dubai
More science events from

Careers

Top

Career snapshots archive
Career snapshots feature people associated with drug discovery and drug development, with the aim of providing expert insights and advice on a wide range of positions and career paths in this field.
Full Text

Top
nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com
More Nature Events

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount
(You will need to log in to be recognised as a nature.com registrant)

For further technical assistance, please contact our registration department

For print subscription enquiries, please contact our subscription department

For other enquiries, please contact our customer feedback department

Nature Publishing Group | 75 Varick Street, 9th Floor | New York | NY 10013-1917 | USA

Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS.

© Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

nature publishing group

No comments: